via Rutgers University
A new method employs weakened viruses as a vaccine to prevent diseases caused by DNA viruses
Rutgers scientists have developed a new approach to stopping viral infections: a so-called live-attenuated, replication-defective DNA virus vaccine that uses a compound known as centanamycin to generate an altered virus for vaccine development.
The method was tested to produce a weakened or “attenuated” version of a mouse cytomegalovirus, a common virus, that has been altered so it can’t reproduce or replicate inside the cell. A replication-defective DNA virus is incapable of replicating its genome, its essential genetic matter. As a result, it is unable to produce an infectious progeny virus in infected cells, and thus restricted primarily to the site of inoculation.
When the weakened viral particles are injected into animals, the researchers said, they stimulate a specific host’s immune system to recognize the invading live virus particles as foreign, causing the virus to be eliminated whenever it is detected.
The new approach, published in Cell Reports Methods, has been shown to effectively shut down viral infections in lab animals.
“We have found that this method is safe; the attenuated virus infects certain cells without proliferating beyond that, and alerts the host to produce specific neutralizing antibodies against it,” said Dabbu Jaijyan, a researcher in the Department of Microbiology at Rutgers New Jersey Medical School and an author of the study. “We see this as a novel method that we hope will accelerate vaccine development for many untreated viral infections in humans and animals.”
The method is called a live-attenuated DNA virus vaccine because it specifically targets DNA viruses – viruses such as cytomegalovirus, chicken pox and herpes simplex that reproduce by making copies of their DNA molecules – and uses an altered DNA virus to fight against them. Developing a method that can quickly and easily generate replication-defective live-attenuated viruses, the researchers said, will accelerate vaccine development for diseases caused by DNA viruses.
The researchers have shown that the method is effective in mice against several DNA viruses, including human cytomegalovirus, mouse cytomegalovirus and herpes simplex virus 1 and 2.
“One of the major advantages of our technology is the safety offered by the robust inhibition of virus replication and that no progeny viruses are produced,” Jaijyan said. “Our technology can be easily applied to any DNA virus to generate live-attenuated replication defective viruses for vaccine development.”
Not all viruses replicate this way. The COVID-19 virus, SARS-CoV-2, for example, is known as an RNA virus because it produces new copies of itself through its RNA. Vaccines against COVID take advantage of that. RNA, which is short for ribonucleic acid, is used to build proteins in SARS-CoV-2.
The DNA virus vaccine method works specifically with DNA viruses because the researchers treat the cytomegalovirus particles destined for use in the vaccine with centanamycin. The compound is known as a DNA-binder because it latches onto organisms’ DNA, including that of DNA viruses, blocking reproduction.
The team is looking to eventually test the method in humans, with the goal to treat cytomegalovirus and other DNA-virus infections.
Cytomegalovirus is a common virus for people of all ages, according to the U.S. Centers for Disease Control and Prevention (CDC). A healthy person’s immune system usually keeps the virus from causing illness. However, infection with cytomegalovirus can have severe consequences in immunocompromised and organ transplant patients. Congenital infection also is the leading cause of birth defects in newborns.
The virus is spread through body fluids, including blood, saliva, urine, semen and breast milk. According to the CDC and World Health Organization, approximately 50 percent of adults around the world have been infected with cytomegalovirus. One in three children is infected with the virus in the U.S. by the age of five.
For the experiment, the researchers grew samples of cytomegalovirus in their lab, purified them, then bathed them in centanamycin. Once injected into lab mice, the weakened virus infects cells but didn’t spread. Over time, the mouse immune system produced sufficient antibodies to shut down the virus and eliminate the infection.
An analysis confirmed that the treated viral cells were not toxic to other cells in the mouse body.
The researchers are continuing to test the method in other medically important viruses, including guinea pig cytomegalovirus as a model to test vaccine efficacy in guinea pigs, with the intention of moving to clinical trials to test the method’s effectiveness in humans.
Original Article: Rutgers scientists produce “DNA virus vaccine” to fight DNA viruses
More from: Rutgers University
The Latest Updates from Bing News
Go deeper with Bing News on:
DNA virus vaccine
- What does science say about mRNA vaccines for pigs?
Any discussion about mRNA vaccines should be preceded by a decent biology lesson, otherwise an interested reader might well get lost before he or she even got started. After all, the article will ...
- New mRNA vaccine fights brain cancer in children by triggering attack from within
RNA, or mRNA, cancer vaccine, that can deliver treatments more effectively in children who have brain cancer and teach their immune systems to fight back.
- HIV and AIDS News
COVID-19 Virus Can Stay in the Body More Than a Year ... Breakthrough in Developing the PD-1-Enhanced DNA Vaccine for Over 6-Year cART-Free AIDS Prevention and Virologic Control Feb. 20, 2024 ...
- New mRNA Vaccines in Development for Cancer and Infections
Prelog also discussed personalized vaccines for cancer immunotherapy. Personalized mRNA vaccines are tailored to the patient's genetic characteristics and antigens. They could be used in cancer ...
- Cancer vaccine breakthrough as first tests show jabs ‘attack killer brain tumours in 48 hours’ and could prevent disease
A NEW mRNA cancer vaccine can reprogram the immune system to attack tumours within 48 hours, a study shows. The first-ever human clinical trial of four adult patients showed the jab helps fight ...
Go deeper with Bing News on:
Live-attenuated, replication-defective DNA virus vaccine
- The Evolving History of Influenza Viruses and Influenza Vaccines
The first influenza vaccine was a monovalent live-attenuated ... between wild-type viruses (for their antigenic properties) and culture-adapted strains (for their replication properties).
- New vaccine may be effective against all coronaviruses
For example, the new vaccine does not include the SARS-CoV-1 coronavirus, which caused the 2003 SARS outbreak, yet it still induces an immune response to that virus. “We’ve created a vaccine ...
- Research aims to develop vaccine against future COVID viruses
Scientists are busy working on a vaccine that might fight strains of the COVID virus SARS-CoV-2 that haven't even emerged yet. The effort from a British team at the University of Cambridge is ...
- Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program
The goal of the contract is to demonstrate the feasibility of manufacturing 1,000 doses of a functional vaccine within seven days. About the Linea™ DNA and Linea™ IVT Platforms The Linea DNA ...
- Vaccine fighting all viruses finally created
UC Riverside researchers have created a novel vaccine employing RNA, that is safe for use by immunocompromised individuals and effective against all strains of the virus. Each year, scientists ...